Número 1 - EII al dÃa
Número 1 - EII al dÃa
Número 1 - EII al dÃa
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
7. Russell RK, Nimmo ER, Satsangi J. Molecular genetics of Crohn’s disease.<br />
Curr Opin Genet Dev 2004;14:264–70.<br />
8. Eckmann L, Karin M. NOD2 and Crohn’s disease: loss or gain of function?<br />
Immunity. 2005;22:661-7.<br />
9. de Vries RR, Huizinga TW, Toes RE. Redefining the HLA and RA association:<br />
to be or not to be anti-CCP positive. J Autoimmun. 2005;25<br />
Suppl:21-5.<br />
10. Ferreiros-Vid<strong>al</strong> I, Barros F, Pablos JL, Carracedo A, Gomez-Reino JJ, Gonz<strong>al</strong>ez<br />
A. CARD15/NOD2 an<strong>al</strong>ysis in rheumatoid arthritis susceptibility. Rheumatology.<br />
2003; 42:1380-2.<br />
11. Klareskog L, Stolt P, Lundberg K, K<strong>al</strong>lberg H, Bengtsson C, Grunew<strong>al</strong>d J,<br />
Ronnelid J, Harris HE, Ulfgren AK, Rantapaa-Dahlqvist S, Eklund A, Padyukov<br />
L, Alfredsson L. A new model for an etiology of rheumatoid arthritis:<br />
smoking may trigger HLA-DR (shared epitope)-restricted immune reactions<br />
to autoantigens modified by citrullination. Arthritis Rheum.<br />
2006;54:38-46.<br />
12. Martin MC, Oliver J, Urcelay E, Orozco G, Gomez-Garcia M, Lopez-Nevot<br />
MA, Pinero A, Brieva JA, de la Concha EG, Nieto A, Martin J. The<br />
function<strong>al</strong> genetic variation in the PTPN22 gene has a negligible effect<br />
on the susceptibility to develop inflammatory bowel disease. Tissue Antigens.<br />
2005;66:314-7.13.<br />
13. Bouma G, Strober W. The immunologic<strong>al</strong> and genetic basis of inflammatory<br />
bowel disease. Nat Rev Immunol. 2003;3:521-33.<br />
14. Weyand CM, Seyler TM, Goronzy JJ. B cells in rheumatoid synovitis. Arthritis<br />
Res Ther. 2005;7 Suppl 3:S9-12.<br />
15. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, Birbara<br />
C, Box J, Natarajan K, Nuamah I, Li T, Aranda R, Hagerty DT, Dougados<br />
M. Abatacept for rheumatoid arthritis refractory to tumor necrosis<br />
factor <strong>al</strong>pha inhibition. N Engl J Med. 2005;353:1114-23.<br />
16. Podolsky DK. Inflammatory bowel disease. N Engl J Med.<br />
2002;347:417-29.<br />
17. Monteleone G, Kumberova A, Croft NM, McKenzie C, Steer HW, Mac-<br />
Don<strong>al</strong>d TT. Blocking Smad7 restores TGF-beta1 sign<strong>al</strong>ing in chronic inflammatory<br />
bowel disease. J Clin Invest. 2001;108:601-9.<br />
18. Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D, Dolin B,<br />
Goodman N, Groden C, Hornung RL, Quezado M, Yang Z, Neurath MF,<br />
S<strong>al</strong>feld J, Veldman GM, Schwertschlag U, Strober W. Anti-interleukin-12<br />
antibody for active Crohn’s disease. N Engl J Med. 2004;351:2069-79.<br />
19. Case JP. Old and new drugs used in rheumatoid arthritis: a historic<strong>al</strong> perspective.<br />
Part 1: the older drugs. Am J Ther. 2001;8:123-43.<br />
20. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi<br />
T, Hashimoto J, Azuma J, Kishimoto T. Treatment of rheumatoid arthritis<br />
with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind,<br />
placebo-controlled tri<strong>al</strong>. Arthritis Rheum. 2004;50:1761-9.<br />
21. Ito H, Takazoe M, Fukuda Y, Hibi T, Kusugami K, Andoh A, Matsumoto T,<br />
Yamamura T, Azuma J, Nishimoto N, Yoshizaki K, Shimoyama T, Kishimoto<br />
T. A pilot randomized tri<strong>al</strong> of a human anti-interleukin-6 receptor monoclon<strong>al</strong><br />
antibody in active Crohn’s disease. Gastroenterology. 2004;126:989-<br />
96.<br />
22. Chang JT, Lichtenstein GR. Drug insight: antagonists of tumor-necrosis<br />
factor-<strong>al</strong>pha in the treatment of inflammatory bowel disease. Nat Clin<br />
Pract Gastroenterol Hepatol. 2006;3:220-8.<br />
23. Sands BE. Why do anti-tumor necrosis factor antibodies work in Crohn’s<br />
disease? Rev Gastroenterol Disord. 2004;4 Suppl 3:S10-7.<br />
24. Iwakura Y, Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Invest.<br />
2006;116:1218-22.<br />
25. Baslund B, Tvede N, Danneskiold-Samsoe B, Larsson P, Panayi G, Petersen<br />
J, Petersen LJ, Beurskens FJ, Schuurman J, van de Winkel JG, Parren PW,<br />
Gracie JA, Jongbloed S, Liew FY, McInnes IB. Targeting interleukin-15 in<br />
patients with rheumatoid arthritis: a proof-of-concept study. Arthritis<br />
Rheum. 2005;52:2686-92.<br />
26. O’Neill LA. Targeting sign<strong>al</strong> transduction as a strategy to treat inflammatory<br />
diseases. Nat Rev Drug Discov. 2006l;5:549-63.<br />
27. Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance<br />
IC, Panaccione R, Sanders M, Schreiber S, Targan S, van Deventer S,<br />
Goldblum R, Despain D, Hogge GS, Rutgeerts P. Nat<strong>al</strong>izumab induction<br />
and maintenance therapy for Crohn’s disease. N Engl J Med.<br />
2005;353:1912-25.<br />
28. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery<br />
P, Close DR, Stevens RM, Shaw T. Efficacy of B-cell-targeted therapy with<br />
rituximab in patients with rheumatoid arthritis. N Engl J Med.<br />
2004;350:2572-81.<br />
46 • Enfermedad Inflamatoria Intestin<strong>al</strong> <strong>al</strong> día - Vol. 6 - Nº. 1 - 2007
Change language